CCL2 and lung cancer: Application of the miR‐210‐3p mimic markedly impaired CCL2 mRNA and its protein levels (Fig. 2H–J), whereas the miR‐210‐3p inhibitor treatment significantly increased CCL2 expressions (Fig. 2K–M) in A549 lung cancer cells.